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Recently it has been hypothesized that blood prestin concentration levels may reflect 
cochlear damage and thus serve as an easily measurable, early sensorineural hearing 
loss biomarker. This is a scoping review aiming to identify and critically appraise 
current evidence on prestin blood levels and their temporal variation in rodents and 
humans with normal hearing and with sensorineural hearing loss. This study was 
designed and held according to PRISMA Extension for Scoping Reviews (PRISMA-
ScR) guidelines. With no limitation with regards to study type, animal and human 
studies focusing on prestin blood levels in normal hearing and in sensorineural hearing 
loss were sought in major databases such as Medline, Central. Scopus, PROSPERO 
and Clinicaltrials.gov. Results have been then hand-searched. A data charting form 
was developed including the parameters of interest. Seven studies focusing on 
measuring prestin blood levels by means of ELISA in rodents and human subjects with 
normal hearing and noise-induced, drug-induced, or idiopathic sudden hearing loss 
were found eligible and were included in the analysis. According to these proof-of-
concept studies, prestin can be detected in the circulation of subjects with no hearing 
loss, however normal ranges remain unclear. After cochlear damage, blood prestin 
levels seem to initially rise and then return to near or below baseline. The degree of 
their change relates with subjects’ degree of hearing loss, damaged cochlear region 
and recovery. Prestin blood levels and their temporal variation seem to correlate with 
cochlear damage, however methodological weaknesses, such as small sample size, 
lack of detailed phenotyping, insufficient exclusion of confounding factors and short 
follow-up do not allow for robust conclusions. To conclude, current findings support 
the value of studying blood prestin levels in normal hearing and hearing loss, and 
highlight a need for larger scale longitudinal research.  
INTRODUCTION 
Biomarkers, or biological markers, are defined as patients’ characteristics that can be 
measured objectively, accurately and reproducibly (“Biomarkers and Surrogate 
Endpoints,” 2001). They serve as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention 
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(Strimbu & Tavel, 2010). In the case of sensorineural hearing (SNHL), which accounts 
for the majority of hearing loss (HL) cases, they could identify early hearing 
impairment, potentially before it becomes measurable by standard audiometric 
procedures.  
To date, no biomarker has been developed or validated in the case of SNHL. However, 
since the pathogenesis of many SNHL types occurs in a specific cell type in the inner 
ear, the outer hair cells (OHCs), these cells are suggested as a good target of future 
research and precision medicine (Eggermont, 2017, 2019; Kujawa & Liberman, 2015; 
Matsuoka et al., 2019). This type of cell is a main and early target of aging, various 
ototoxic substances and overexposure to noise or acoustic trauma (Kujawa & 
Liberman, 2015; Ryan et al., 2016). OHC loss or dysfunction may, in addition, have a 
pathogenetic role in idiopathic SNHL (ISSHL) (Sun et al., 2019). Consequently, 
discovery of an OHC-specific biomarker and the assessment of the conditions under 
which it could help in the diagnosis and management of SNHL is of great priority.  
Prestin is the 5th member of an 11-member membrane transporter super family (solute 
carrier family 26 or SLC26) which includes anion transporters and related proteins (He 
et al., 2014; Liberman et al., 2002). Prestin is exclusively produced in the cochlea. 
More specifically, it is situated in the lateral wall of OHCs and is responsible for their 
electromotility (Liberman et al., 2002; Parham, 2015).  Prestin’s exact role and 
regulation mechanisms have not been completely clarified (Matsunaga & Morimoto, 
2016; Mazurek et al., 2007; Xia et al., 2013). Its deficiency is associated with moderate 
SNHL. In mice, prestin gene deletion can cause loss of OHC electromotility in vitro 
and 40-60 dB loss of cochlear sensitivity in vivo, while heterozygotes present a 6 dB 
elevation of hearing thresholds (Liberman et al., 2002). Moreover, in vitro OHC 
damage due to ototoxic substances and high-intensity noise increases the expression 
rate of the responsible gene (Mazurek et al., 2007; Xia et al., 2013). To date, there is 
only one observational study assessing the auditory results of prestin gene mutation 
in humans (two identical twins); its results also imply a sensorineural loss of about 40-
60 dB (Matsunaga & Morimoto, 2016).  
Apart from cochlear prestin, circulating prestin has also been observed in the blood of 
animals and human with or without HL (Dogan et al., 2018; Parham, 2015; Tovi et al., 
2018). Its presence in the blood has been detected by means of enzyme-linked 
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immunosorbent assay (ELISA) and could be explained either by its small size (80 
kDa), which may allow crossing of the blood-labyrinthine barrier, or by its engulfment 
by phagosomes after OHC apoptosis. ELISA is capable of detecting blood prestin 
even in small quantities, where less than 1% of OHCs are lost (long before audiological 
symptoms or abnormal audiometric outcomes appear) (Parham, 2015). 
All the above arguments have led to the hypothesis that prestin blood levels could 
reflect changes or damage in the cochlea, and more specifically in the OHCs, and thus 
serve as an easily measurable, early SNHL biomarker (Parham, 2015). Consequently, 
evaluating potential changes in prestin blood concentration in patients suffering from 
SNHL has attracted researchers’ interest. A scoping review of all the available 
scientific evidence could help the design and execution of further research in this 
particular domain. To the best of our knowledge, no such review has been conducted 
to date.  
 
MATERIALS AND METHODS 
Objectives 
This is a scoping review of current clinical and basic science literature on the 
measurement of prestin levels in the blood of normal and hearing-impaired animals 
and human subjects, aiming at systematically mapping the research conducted in this 
area. Identification of the limitations of previous works, methodological pitfalls, or gaps 
in current knowledge, are a prerequisite in order to understand under which conditions 
prestin blood levels can have a meaningful interpretation.  
The following research question was formulated: What is known from the literature 
about prestin blood levels and its temporal variations in people and animals with or 
without SNHL?  
Methods 
The protocol of this study was drafted according to PRISMA Extension for Scoping 
Reviews (PRISMA-ScR) guidelines (Shamseer et al., 2015; Tricco et al., 2018).    
Eligibility criteria 
Population: humans and animals with or without SNHL 
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Intervention: measurement of prestin blood levels  
Comparator: not applicable 
Outcome: prestin blood levels in healthy controls and hearing impaired, temporal 
variation of prestin blood levels, correlation of prestin blood levels with HL 
Inclusion Criteria: controlled experimental studies [controlled clinical trials (CCTs) and 
randomized controlled trials (RCTs)], observational studies [longitudinal and cross-
sectional studies], reviews. Publication type and language: English, French, Spanish 
or German-language journal articles. Publication year: last 10 years. Particulars: There 
was no restriction in types of SNHL. Sudden HL, noise trauma, hereditary HL etc., 
were all included in the review. Both human and non-human studies have been 
included. 
Exclusion Criteria: Studies in languages other than the aforementioned ones. No full 
text available.  
Information sources 
Major databases of Medline, Central and Scopus were searched for eligible studies by 
two reviewers independently. The grey literature was sought in PROSPERO, 
Clinicaltrials.gov, EU Clinical Trials Register and the lists of abstracts in major 
Audiology- and Otoneurology-related conferences of the past six years. The results 
were then hand-searched (Hopewell et al., 2002). 
Search 
The Medline search was conducted via Pubmed by using free text and MeSH terms. 
Predefined search strategies and selection criteria were used to evaluate the eligibility 
of studies. Final syntax follows: 
(prestin) AND ((hearing loss) OR (hearing impairment) OR "Hearing Loss"[Mesh] OR 
"Hearing Loss, Sensorineural"[Mesh] OR "Hearing Loss, Noise-Induced"[Mesh] OR 
"Hearing Loss, Sudden"[Mesh] OR "Deafness"[Mesh]) 
Adding a third search term such as “ELISA”, "Enzyme-Linked Immunosorbent 
Assay"[Mesh] or “antibodies” was finally rejected since a number of studies were 
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omitted. The NOT Boolean Operator was tried in an effort to exclude conductive-HL-
focused studies, but it was finally rejected since it did not change the number of results. 
Search in the other aforementioned databases followed the same principles, using 
keywords and MeSH terms wherever available. Since this review is focusing only on 
studies measuring prestin in the blood and this has been introduced as a procedure 
only recently (Parham et al., 2014), our research was limited to the last ten years.  
Selection of sources of evidence 
All studies were screened, first by title and abstract and subsequently by full text in 
order to identify and exclude those that were irrelevant, duplicates, or in other than the 
approved language.  
Data charting  
A data charting form was developed including the parameters of interest for the 
particular study.  
Data items 
Data about article identification (author, journal. year of publication), article 
characteristics (e.g., country of origin, language, funding), population characteristics 
(human or other species, age, type of HL), prestin level measurement (methodology, 
setting, results) were extracted from the included studies. A comprehensive summary 
will be presented in Results (section 3.2). 
Synthesis of results 
We present the included studies and summarize the type of settings, populations and 
study designs, with emphasis on our predefined scientific queries (study’s timeline, 
results in prestin blood level as measured in controls and hearing-impaired subjects). 
RESULTS 
Selection of sources of evidence 





Fig. 1. Selection of sources of evidence. Seven studies fulfilled the predefined 
inclusion criteria.  
Characteristics of sources of evidence 
Article identification information (author, year and journal of publication etc.) and 
comprehensive comments on the methodology and results of each one are included 







Table 1. Characteristics of included human studies. All prestin blood level 
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Table 2. Mean prestin concentration levels in two human studies. 
 Patients Controls p-value 
Hana and Bawi, 2018 
300 workers with 
NIHL 
200 workers with 
normal hearing 
 
Prestin Level in pg/ml (SD), 
before treatment 
169 (88.4) 100.9 (16.7) 0.04* 
Prestin Level in pg/ml (SD), 1 
month after treatment 
114 (99.2) - 0.04* 
Sun et al., 2019 
14 patients with 
ISSHL 
24 with normal 
hearing 
 
Prestin Level in pg/ml (SD), 
before treatment 
1955.98 (2501.48) 840.24 (496.22) <0.01* 
Prestin Level in pg/ml (SD), after 
treatment 
1653.26 (1967.60) - 0.06 
SD, standard deviation; ISSHL, idiopathic sudden sensorineural hearing loss; NIHL, noise 
induced hearing loss 
* significant at an alpha of 0.05 
 p-value for comparison between patients and controls 
 
 
Prestin blood levels without hearing loss or noise trauma 
Four out of seven included studies evaluated the levels of prestin in the blood of human 
subjects or animals with no HL or exposure to noise or to ototoxic agents. In a recent 
clinical study by Sun et al. (2019), 24 people (13 females) referred as of normal hearing 
capacity were age- and sex-matched to 14 (eight females) idiopathic sudden 
sensorineural hearing loss (ISSHL) patients. In this control group, which had no 
hearing loss history, prestin levels ranged from 85.4 to 1628.25 pg/mL, with an 
average of 840.24 (± 496.22) pg/mL [mean (SD)]. Mean age was higher than 54 years, 
however no further information on the control group’s characteristics was available 
(Table 1). 
A larger scale cross-sectional study by Hana and Bawi (2018), assessing prestin blood 
levels in 300 workers with noise-induced hearing loss (NIHL), also showed that prestin 
was present in the blood of 200 volunteers that served as controls [100.9 (± 16.7) 
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pg/mL, mean (SD)] (Table 2). The mean age of the control group was estimated at 
40.3 (± 3.9) years. Their occupational exposure to noise was measured using a sound 
level meter at their workplace and reported according to the duration of occupational 
noise exposure in months [18.2 (± 7.4) months, mean(SD)] and exposure levels [87.0 
(±7.6) dBA, mean (SD)] separately. Overall exposure was unclear since recreational 
exposure was not reported. The above information allowed the authors to match the 
control to the patient group by age, gender, and occupational exposure. The authors 
also asked patients and controls for a history of ototoxic drugs usage, hearing-related 
family history, and smoking, although they only controlled for smoking in the analysis.  
Animal studies have also shown that prestin can be detected in controls’ blood. 
Parham et al. (2019) observed that prestin levels ranged from 125 to 245.7 pg/mL 
[177.9 (± 4.3) pg/mL, mean (SD)] in 46 male Wistar rats with no prior exposure to 
ototoxic noise or drugs. In another male Wistar rat model, measuring prestin levels 
after exposure to ototoxic factors (amikacin, cisplatin), Dogan et al. (2018) also 
showed that prestin could be detected in the blood of the control, ototoxic-drug-free, 
group [n=10, 377.0 (± 135.3) pg/ml, mean (SD)].  
 
Relation of blood prestin levels to hearing loss 
All included studies were focused on SNHL. Sun et al. (2019) included patients 
hospitalized with ISSHL. Hana and Bawi (2018) evaluated prestin blood levels in 
patients with NIHL. Animal studies included rats and guinea pigs that were exposed 
to ototoxic substances, such as aminoglycocides and cisplatin (Dogan et al., 2018; 
Liba et al., 2017; Naples et al., 2018), and thus present SNHL due to ototoxicity; or to 
hazardous levels of noise, and thus present NIHL (Parham et al., 2019; Parham & 
Dyhrfjeld-Johnsen, 2016). 
In the ISSHL study of Sun et al. (2019), 14 participants with mean age 57.9 (± 15.4) 
years [mean (SD)] presented significantly higher levels of prestin in their blood before 
treatment compared to controls (p<0.001, statistical test not reported). All 
measurements before treatment were conducted within seven days from the onset of 
HL and ranged from 190.30 to 9648.80 pg/mL, with a 1955.98 (± 2501.48) pg/mL 
[mean (SD)] average concentration. Half of ISSHL patients presented higher 
concentration levels compared to the average value for the control group and 35.7% 
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of ISSHL participants had higher prestin levels than the highest value detected in the 
control participants.  Measurements were repeated at the end of treatment, within 4 – 
11 days after the initial measurement, and ranged from 0 to 7610.45 pg/mL, with an 
average concentration of 1653.26 (± 1967.60) pg/mL [mean (SD)]. Prestin blood 
concentration before treatment did not correlate with treatment outcomes (Table 2). 
Six out of 10 participants who recovered from ISSHL had decreased blood prestin. All 
four participants that did not recover presented increased prestin levels. 
In the human NIHL study, Hana and Bawi  (2018) revealed a significant difference in 
prestin blood levels between the patient and control group immediately after noise 
exposure (Table 2). In comparison to controls, NIHL patients’ age, gender ratio, 
smoking habits and occupational exposure to noise [18.6 (± 7.6) months, mean (SD) 
and 87.0 (±7.6) dBA, mean (SD)] did not differ significantly. One month after treatment 
(no information on type of treatment was provided), mean prestin concentrations in the 
NIHL group were 55% lower than that initially observed [114 (±99,2) pg/ml, mean 
(SD)]. These values differed significantly from the ones before treatment (t = 4.3, p = 
0.02) and from the control group (Table 2). Significant positive correlations were 
reported between prestin level and severity of hearing loss (r = 0.971), otolin-1 level (r 
= 0.776), 8–OhdG (r = 0.556), and Cys/Cys genotype (r = 0.828).  
The effect of the noxious agent (noise or drug) in rodent models has been verified in 
all relevant studies by means of histological and audiometric testing [Auditory 
Brainstem Responses (ABR) and/or Distortion Product Otoacoustic Emissions 
(DPOAEs)]. Liba et al. (2017) observed an increase in blood concentrations of prestin 
both in guinea pigs that had an increase in ABR thresholds and in mice that were 
found resistant to cisplatin according to their audiometric evaluation.  
Dogan et al. (2018) exposed rats to low and high doses of amikacin (200 and 600 
mg/kg/day, respectively) for 10 days and cisplatin (single dose of 5 and 15 mg/kg, 
respectively) for 3 days and conducted prestin measurements immediately after the 
end of the experiment. They report that their audiometric findings via DPOAEs showed 
significant changes at specific frequencies (4, 6 and 8 kHz). Mean prestin blood levels 
were found to be 411.3 (± 73.1) pg/mL [mean (SD)] in the low-dose amikacin group 
and 512.6 (± 106.0) pg/mL [mean (SD)] in the high-dose amikacin group. 
Corresponding values for cisplatin were 455.0 (± 74.2) pg/mL [mean (SD)] in the low-
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dose group and 555.3 (± 47.9) pg/mL [mean (SD)] in the high-dose group (Dogan et 
al., 2018). Significant differences were found in blood prestin between the low and 
high amikacin groups, between the low and high cisplatin groups, and for all treatment 
groups compared to controls [377.0 (± 135.3) pg/ml, mean (SD)]. Prestin blood levels 
were significantly correlated with the threshold changes in those frequencies where a 
significant threshold shift was detected in the DPOAEs. In the study of Parham and 
Dyhrfjeld-Johnsen (2016), blood prestin concentration showed a linear negative 
relationship with DPOAE level change (r=0.563, p=0.01) and a linear positive 
relationship with ABR threshold change (r=0.46, p=0.036) at 14 days after exposure 
to noise. Naples et al. (2018) found that the increase in ABR threshold was recovered 
at day 7 and 14 in the guinea pigs that received diltiazem as otoprotectant after 
cisplatin exposure. Prestin blood concentrations were in accordance with these 
functional results, and no significant change in prestin levels was observed in the 
diltiazem group. 
Parham et al. (2019) included histological testing, ABR and DPOAEs to the 
assessment of cochlear damage due to exposure to 110 dB (low noise group) and 120 
dB SPL (high noise group).  In this particular study, agreement was observed between 
functional, histological and serological findings: significantly greater loss of OHCs was 
observed in the 120 dB SPL group and was associated with a greater extent of 
functional changes and decrease in prestin levels compared to the 110 dB SPL group. 
Variation in prestin blood levels over time after cochlear damage 
In the recent animal study by Parham et al. (2019), prestin levels were measured at 4 
h, 24 h, 48 h, 72 h, 7 and 14 days after 2 h of exposure to noise of 110 and 120 dB 
SPL. The study found a noise-level-dependent change of prestin over time; after an 
initial peak of prestin concentration right after the noise trauma (4 h), the overall (14 
days) statistically significant decrease of prestin concentration in comparison to pre-
exposure values was found to be less than 5% for the low-dose group (approximately 
10 pg/ml) and more than 10% for the “loud” group (approximately 30 pg/ml). Two 
additional animal studies provide information on change of prestin levels over time; 
the first study by Parham and Dyhrfjeld-Johnsen (2016) evaluated blood prestin 14 
days after noise exposure (rats). The second one by Liba et al. (2017) at 1, 3, 7, 14 
days after one single dose of cisplatin at 8 mg/kg (rats and guinea pigs). The first study 
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found that blood prestin concentrations in noise exposed rats were significantly below 
control levels at day 14 after the noise trauma (Parham et al., 2019). The second study 
reports that prestin rose to a maximum value on day 7 (mice) and day 3 (guinea pigs) 
after cisplatin treatment and then declined back to or below baseline/control levels on 
day 14 (Liba et al., 2017). 
Naples et al. ( 2018) explored prestin blood level changes over time after exposure to 
ototoxic substances.  Prestin levels were measured at 1, 2, 3, 7, and 14 days post-
cisplatin administration in 20 guinea pigs. Ten of them received treatment with 
diltiazem (as otoprotection), while 10 received saline and served as controls. In this 
particular study, the diltiazem group had no significant change of prestin levels before 
and after cisplatin. In the control group, the rise from baseline values reached a 
maximum at day 2 post-cisplatin administration and remained elevated at day 3 before 
trending back toward baseline at days 7 and 14. The mean percentage changes in 
prestin level for days 1 to 3 were statistically significant compared to baseline.  
A summary of the results of prestin concentration after trauma is provided in Figure 2. 
It should be noted that no specification of the time of day or point on circadian cycle 


































Parham et al, 2019,
rats, 110 dB SPL for 2h
Parham et al., 2019, 
rats, 120 dΒ SPL for 2h












Fig. 2. Average prestin concentrations as a function of time after trauma in the two 
NIHL rodent models over time (A) and in the three drug ototoxicity rodent models (B). 
(Data extracted from the original graphs via WebPlotDigitizer) 
* HAG = 600 mg/kg/day of amikacin (10 days), LAG = 200 mg/kg/day of amikacin (10 
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It has been hypothesized recently that, apart from the changes due to normal prestin 
turnover within OHCs, blood prestin concentrations may also be related to cochlear 
damage (Parham, 2015). Building on this idea, prestin blood levels have been 
measured in several rodent and human studies with NIHL, ISSHL, or drug-induced 
HL. The rationale for these studies is that these types of SNHL seem to be associated 
with OHC damage (Ryan et al., 2016; Tovi et al., 2018). ELISA is the only blood prestin 
detection method that has been identified in the present review (Table 1 and SM Table 
1). A new electrochemical immuno-biosensor for circulating biomarkers of the inner 
ear (otolin-1 and prestin) has been recently proposed (Mahshid & Dabdoub, 2020). 
Nevertheless, no data from rodent or human studies are yet available, and further 
research is needed before validating the conditions under which this method can be 
used in research and clinical practice. 
An increase in blood prestin concentrations in the case of OHC damage or loss may 
be explained by the release of prestin from the OHCs directly through the blood-
labyrinth barrier or by means of phagosomes in the supporting cells (in the short term) 
and/or the functional up-regulation of prestin expression in the residual OHCs (longer 
term) (Abrashkin et al., 2006; Liba et al., 2017). Although, there is controversy 
concerning the correlation of prestin mRNA levels to prestin protein levels (Cheatham 
et al., 2005; Liberman et al., 2002), data from 5- to 6-week-old wild-type CBA/CaJ 
mice show that prestin has been up-regulated by 32–58% within remaining OHCs after 
noise exposure (Xia et al., 2013). Similarly, in 5-week-old wild-type CBA/CaJ mice with 
diphtheria toxin-induced SNHL (intraperitoneal injections of diphtheria toxin, 50 ng/g 
for three days in a row) prestin up-regulation seems to be locally regulated by the 
steady-state transducer bias current with no involvement of centrally mediated efferent 
feedback (Roux et al., 2006; Song et al., 2015). Based on current evidence, it is difficult 
to conclude whether the increase of prestin blood concentration reflects cochlear 
damage directly, via passage of free prestin molecules to the circulation, or a cochlear 
compensation mechanism for temporarily or permanently damaged hair cells through 
up-regulation of the prestin gene in the remaining OHCs. It is also unclear how any 
up-regulation of the prestin gene may reflect to inner ear prestin levels or to prestin’s 
blood concentration. Better understanding of the pathophysiological mechanisms that 
are involved in noise-induced cochlear damage and prestin up-regulation may clarify 
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the source of the post-noise exposure increase of prestin blood concentration 
observed in the studies mentioned in this review. 
A decrease in blood prestin concentration in the case of OHC damage or loss may be 
the product of a dynamic equilibrium of cochlear function where the remaining, fewer 
OHCs release less prestin into circulation (Parham et al., 2019). Decreased blood 
prestin may also be a consequence of the disruption of the balance between the 
production of free radicals and the antioxidant defense system in the cochlea that can 
occur after exposure to intense noise or other noxious agents. Hana and Bawi (2018) 
observed a significant positive correlation between prestin blood levels and blood 8-
OHdg. Nevertheless, evidence from age- and noise-related hearing loss rodent 
models shows that intracochlear reactive oxidative species (ROS) accumulation may 
affect, to some degree, OHCs’ lateral wall and electromotility (Chen, 2006; Chen et 
al., 2009; Lee et al., 2019). OHC structure changes may decrease prestin’s cellular, 
and thus free intracochlear, concentration, which may consequently have an effect on 
its blood concentration. Intracochlear ROS may lead to oxidation of different elements 
of the prestin molecule or to the formation of protein–protein cross-linkages (Berlett & 
Stadtman, 1997; Chen, 2006). 
Over the studies reviewed here, a short-term increase in prestin blood concentration 
and a long-term decrease below baseline has been observed following trauma. This 
finding agrees with previous studies on prestin gene regulation. Prestin up-regulation 
has been shown in rats with verified HL (functional and histological assessment) after 
exposure to noise (10-20 kHz, 110 dB SPL for 4 h). In this animal model, prestin 
expression peaked at third post-exposure day (4.9 ± 0.3 folds of increase) and 
returned progressively to baseline four weeks after noise exposure (Chen, 2006). 
Similarly, in another rodent model, after monaural noise exposure, change of 
endocochlear prestin mRNA levels was associated with the degree of hearing loss 
and differed among different parts of the cochlea (increased with a base-to-apex 
gradient (Mazurek et al. 2007). At first, exposed rats and guinea pigs presented 
moderate NIHL (15–25 dB DPOAE threshold shift), and prestin mRNA increased. 
One-week post-exposure, NIHL severity had increased (by about 30 dB) and prestin 
blood levels tended to decline. Interestingly, DPOAE decrease and prestin up-




Long-term prestin regulation in the case of SNHL remains unclear. 
Immunohistochemical staining of the cochlea of F344 rats with age-related hearing 
loss has indicated that prestin is reduced and that this age-related reduction may 
precede hair cell degeneration (Chen et al., 2009). Nevertheless, data concerning 
human prestin regulation and blood concentration is still missing.  
Prestin blood levels without hearing loss or noise trauma 
It has been hypothesized that prestin is detected in the blood of “naïve” rodents due 
to its normal turnover in the OHC membrane (Parham & Dyhrfjeld-Johnsen, 2016). 
This may further imply that normal values differ per species and are correlated with 
the number of OHCs and the length of the cochlea (Liba et al., 2017).  In human 
studies, prestin was found in the blood of people identified as of “normal hearing” 
(Hana & Bawi, 2018; Sun et al., 2019). However, there is a lack of information 
concerning their medical and noise exposure history and their full audiometric profile. 
This information is necessary in order to confirm that their hearing status was indeed 
healthy. Additional data on prestin levels in people of different ages, who would have 
a full history and audiometric profiling, would be extremely useful in developing norms 
and determining which prestin levels are part of the normal physiological turnover of 
OHCs and which indicate cochlear damage. 
Relation of plasma prestin levels to hearing loss 
Prestin blood concentration changed significantly in rodents with acquired HL when 
compared to baseline measurements or controls (Dogan et al., 2018; Parham et al., 
2019; Parham & Dyhrfjeld-Johnsen, 2016). Using non-exposed “naïve” rodents and 
assessing the effect of noise or ototoxic agents on their hearing by means of 
histological and functional assessment allows the safe correlation of each change in 
prestin levels with specific phase of cochlear damage.  
Previous studies on intra-cochlear prestin expression indicate its base-to-apex 
gradient increase and its association with the degree of HL (Chen, 2006; Mazurek et 
al., 2007). Similarly, blood prestin levels show an association to the cause and degree 
of cochlear damage. In the case of NIHL, prestin levels have been associated with the 
levels of noise exposure and the degree of temporary and permanent threshold shift 
that has been caused. In the study of Parham et al. (2019), 20 rats exposed to intense 
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octave band noise at 120 dB SPL showed significant changes in prestin concentration 
when compared to the changes observed in the 110 dB SPL exposed group. In the 
case of ototoxicity, groups with high doses of cisplatin and amikacin presented both 
higher degrees of hearing loss and prestin blood concentration (Dogan et al., 2018). 
A very interesting finding is that, in specific cases, prestin expression change precedes 
auditory findings and/or may have a higher predictive value than audiometric 
assessment. Liba et al. (2017) observed a rise in blood prestin levels at day 2 post-
cisplatin administration. This rise preceded the onset of significant ABR changes. This 
observation may be explained by the fact that early up-regulation of intra-cochlear 
prestin may maintain normal cochlear function. The findings of Parham et al. (2019) 
on NIHL suggest that an early rise of blood prestin is a better prognostic marker than 
ABR or DPOAEs threshold shifts. Nevertheless, it is not clear if, and under which 
conditions, prestin blood concentration is indeed more sensitive than standard 
audiometric testing. Further research, combining histological examination of the 
cochlea, DNA expression determination, functional auditory testing and ELISA could 
clarify better the correlations and time sequencing among cochlear trauma, OHC loss, 
prestin gene expression, prestin protein endocochlear / blood concentration and 
auditory function. 
In the human ISSHL study, Sun et al. (2019) found a significant difference in prestin 
blood levels between patients and controls (Sun et al., 2019) However, only half of the 
ISSHL participants had higher levels of prestin blood concentration when compared 
to controls. According to the authors, this finding suggests that only some of the ISSHL 
patients present true OHC damage and that prestin could serve as a means of their 
identification. However, before being able to generalize this claim, larger scale data 
on hearing phenotypes of ISSHL patients and controls are needed. Prestin 
concentration has shown some association with the degree of recovery, but more data 
are needed before being able to generalize this finding. In the NIHL study by Hana 
and Bawi, patients’ prestin was significantly greater, both before and after treatment 
(1 month later) when compared to controls (Hana & Bawi, 2018). However, as 
mentioned before, methodological issues of those studies (small sample size, 
incomplete audiometric profiling and unclear timeline of measurements) do not allow 
their results to be generalized easily. 
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Variation in prestin blood levels over time after cochlear damage 
Recent evidence implies that there is a circadian regulation of auditory function and 
noise sensitivity (Basinou et al., 2017). Quantitative real-time polymerase chain 
reaction has revealed circadian regulation of various endocochlear transcripts, while 
specific neurotrophic factors that are associated with cochlear neurogenesis and 
homeostasis, such as brain-derived neurotrophic factor (BDNF), have also shown a 
circadian pattern (Singer et al., 2014).  Current evidence from rodent and human 
studies does not clarify the effect of circadian regulation on prestin blood levels.  
Preliminary data from animal and human studies have shown that prestin blood levels 
depend on the interval between the exposure to the ototoxic agent (drug or noise) and 
its measurement by means of ELISA. Two rodent models have shown that prestin 
presents an increase in the blood immediately after exposure to noise and then returns 
to baseline, or below baseline values, 14 days after (Parham et al., 2019; Parham & 
Dyhrfjeld-Johnsen, 2016). No data later than 14 days after trauma are available to 
date. No information on the specific time of the day that the ototoxic agent was applied 
or the blood was drawn is available either. 
To date, no human studies have assessed prestin blood level variation over time after 
exposure to noise or to an ototoxic agent in the absence of potential confounding 
factors after the initial time point, such as continuation of the exposure to the noxious 
agent (noise or ototoxic drug) or participants’ therapeutic treatment for hearing loss.  
In order to assess the true change of blood prestin after cochlear damage, factors that 
may potentially affect its intracochlear regulation and concentration should be avoided 
after baseline measurement, and all variables but time should be held constant. 
Consequently, longitudinal human studies focusing on prestin concentration over time 
are warranted.  
In the two human models included in this review, prestin was measured before and 
after treatment for NIHL and ISSHL (Hana & Bawi, 2018; Sun et al., 2019).  However, 
no specific timeline of participants’ HL or the relation between day of onset of the HL 
or HL diagnosis and the day of prestin measurement was provided. No information on 
the specific time of the day that participants were exposed to noise, or that the blood 
was drawn, is available either. 
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It should be noted that if prestin levels return to near-normal shortly after trauma, then 
they may be of little use in the diagnosis of established HL. Further research with 
multiple measurements during day- and night-time, for different hearing phenotypes, 
with and without exposure to noxious agents (e.g., noise), is needed to evaluate this. 
Long-term prestin gene functional expression and prestin protein release into 
regulation also needs further understanding.  
Methodological pitfalls  
Over the human studies reviewed here, there is great heterogeneity in primary 
endpoints, such as the mean prestin concentration levels and their range both in 
control and patient groups. There is also a lack of detail on important methodological 
issues. These differences could explain the heterogeneous results.  
Age is another parameter that may be associated with the variability of prestin blood 
levels. Data from rodent models show that prestin levels in OHCs, evaluated semi-
quantitatively by immunohistochemical staining, are reduced in the aging cochlea of 
F344 rats (Chen et al. 2009).  
With regards to sample characteristics, other parameters may also affect prestin 
concentration levels and should be better clarified before drawing any conclusions. 
Different causes of HL are linked to different pathophysiological mechanisms and 
possibly different endocochlear and blood behavior. In a recent human study focused 
on ISSHL, Tovi et al. (2018) state that ELISA detected anti-prestin antibodies in the 
serum of only two out of 63 patients with unilateral ISSHL. These findings, along with 
the fact that ISSHL pathophysiology remains unclear and differs from NIHL, makes  
comparison of the two human studies reviewed here challenging (Greco et al., 2011). 
Duration of the symptoms, age of onset, severity of HL, and interval between treatment 
and onset of HL, are all considered as SNHL prognostic factors. In the NIHL study by 
Hana and Bawi, it is described that patients were referred to the hospital because of 
NIHL, received treatment, and were tested for prestin blood levels before and after this 
treatment. It is mentioned that tinnitus and HL were the main symptoms. However, 
information is lacking on whether acoustic trauma was acute or chronic, and on the 
specific kind of treatment patients have undergone. This information is important since 
different pathophysiological mechanisms could be involved (Le et al., 2017). 
Concerning the audiometric profile of patients, they have been classified according to 
their degree of HL as it was defined by average threshold at 0.5, 1, 2, 3, 4, 6 kHz in 
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the pure tone audiogram. No further audiometric evaluation was conducted (Hana & 
Bawi, 2018). Similarly, in the ISSHL study of Sun et al. the prestin concentrations of 
14 participants were included in the analysis, without any detail on their clinical 
variables being taken into account.  
Hana and Bawi (2018) matched the two groups by age, gender, and occupational 
exposure. They asked patients and controls for a history of ototoxic drug usage and 
hearing-related family history, but they did not control for these in the analysis. They 
also included questions about work and disease history, however this information is 
not reported in the article. Participants of the profound hearing loss group were 
removed from the noisy environment and the study, however no information is given 
concerning the continuation or not of noise exposure for the participants with mild, 
moderate and severe HL (Hana & Bawi, 2018). If during their treatment, and thus 
participation in the study, participants remained working in the same noisy 
environment, this could be considered as a confounding factor. Sun et al. (2019) 
excluded participants with other sources of HL. Nevertheless, no particular measures 
were taken to exclude participants with age-related or overall-noise-exposure-related 
cochlear damage. This fact, along with the small sample size, does not allow strong 
conclusions about the relation of ISSHL pathophysiological pathways and blood 
prestin level changes to be drawn. 
Understandably, the aforementioned factors were better controlled in the rodent 
models. In the animal studies presented in this review, all animals were healthy, 6-20 
weeks of age and with no prior exposure to ototoxic agents or noise before undergoing 
the experimental procedures (exposure to cisplatin, aminoglycocides, or noise). In 
order to confirm cochlear damage, rodents exposed to noise or other noxious agents 
underwent functional or histological testing. Degree of cochlear damage and HL was 
evaluated by means of ABR and DPOAEs, while three studies also included 
histological examination of the cochlea (Dogan et al., 2018; Parham et al., 2019; 
Parham & Dyhrfjeld-Johnsen, 2016). In two of them, Parham et al. used the same 
methodology and focused on the mean loss of OHCs in each group as a function of 
normalized distance from the apex, using the total length of each histological 
specimen. In the context of the third study by Dogan et al. a pathologist blinded to the 
groups scored the specimens for their OHC count (number of OHCs with an intact 
nucleus) according to the four-point scoring system for cisplatin-induced ototoxicity 
defined by Freitas et al. (Freitas et al., 2009). As a consequence, each deviation from 
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baseline in the functional, histological or prestin concentration outcomes can be safely 
attributed to the HL originating from experimental interventions.  
Concluding, the discovery and validation of otologic biomarkers in human blood may 
be of great value to the prevention, early diagnosis, and prognosis of hearing loss. To 
date, there is some evidence that prestin blood concentrations change in the case of 
acquired HL in rodents, and that this change is correlated with the degree of cochlear 
damage, the region of the cochlea that is affected, and the time interval between onset 
of disease and prestin measurement. These proof-of-concept studies provide 
important insight on the matter and provide preliminary evidence that prestin may 
indeed serve as a valuable biomarker for HL. However, larger scale data are required 
in order to clarify the conditions under which blood prestin can be best used as a 
marker in the case of human subjects with SNHL. In human studies, specific 
methodological challenges have to be resolved before researchers are able to draw 
any conclusions. Future studies could be improved by larger samples, more detail on 
hearing phenotyping and clinical variables, prestin measurements at specific time 
points during the course of cochlear damage, clear segregation of the effect that 
temporary threshold shift has on prestin from the effect of permanent lesions, longer 
longitudinal experiments in unilateral and bilateral acquired HL, full audiometric 
profiling of subjects, detailed quantification of all factors that could have led to OHC 
damage, and definition of the clinical and genetic variability of each HL case.  
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SM Table 1.  Characteristics of included animal studies. All prestin blood level 
measurements were conducted by means of ELISA. 
Author, Year, 
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Title Population Summary Audiological 
Assessment 
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prestin blood levels at 
4 h, 24 h, 48 h, 72 h, 
7 and 14 days in 20 
rats exposed to 
intense octave band 
noise for 2 h at either 
110 or 120 dB SPL. 
Comparison with 26 
naïve male rats. 
Auditory brainstem 
responses 
(Tone-pips with 2 ms 
duration, 300 repetitions 
at a rate of 20/s, from 10 
to 90 dB SPL with a 5 





(80 /70 dB SPL, with an 
f2/f1 ratio of 1.2. At 4, 8, 
16, 24, and 32 kHz) 
Day 0 & 14 
 
[Histological evaluation 
of hair cell loss was held 
at day 14] 
110 dB SPL group: 
Statistically non-
significant, <5%, rise 
of prestin 
concentration at 4 
hours post exposure, 
then a statistically 
significant gradual 
decrease to 10pg/ml 
(compared to 
baseline) at 14 days 
after exposure. 
120 dB SPL group:  
6 subjects presented 
increased prestin 
levels at 4 hours 
post exposure (22.8 
± 9 pg/mL) and 4 
subjects decreased 




decrease of prestin 
levels (compared to 
baseline) was 
observed at day 14  
after exposure. 








prestin as a 
predictive 
marker for the 
early 
detection of 







prestin blood levels in 
35 rats that received: 
200 mg/kg/day of 
amicacin for (10 
LAG), 600 mg/kg/day 
of amicacin for 10 
days (6 HAG), one 
single dose of 5 
mg/kg (9 LCIS), one 
single dose of 15 
Distortion product 
otoacoustic emissions 
(70/70 dB SPL, with an 
f2/f1 ratio of 1.22. at 
2001, 3154, 4003, 6298 
and 7998 Hz) 
 
[Histological assessment 
of stria vascularis, organ 
of Corti, spiral ganglion 
according to 4-point 
scoring system for 
Dose-dependent 
cochlear damage 





mg/kg (10 HCIS) and 
10 controls.  
cisplatin-induced 
ototoxicity defined by 
Freitas et al.] 











a Guinea Pig 
Model 
Guinea pigs Measurement of 
prestin blood levels 
performed at days 0, 
1, 2, 3, 7, and 14 
post-cisplatin 
administration, in two 
groups of guinea pigs 
(one treated with 




- tone bursts of 4, 8, 
16, 24, and 32 kHz, 
5-ms (2-ms rise/fall 
time), delivered at a 
rate of 21/s 
- click-evoked 
Rise in blood prestin 
levels (25.6%) at day 
2 post cisplatin 
administration 
(precedes onset of 
significant ABR 
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30 mice and 10 
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14 days after 1 single 
dose of cisplatin at 8 
mg/kg. (five mice 
were sacrificed at 
each time point, all 
guinea pigs were 
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concentrations rise, 
peak on days 7 
(mice) and 3 (guinea 
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below baseline / 
control levels 14 






















prestin blood levels in 
21 rats of 6-11 weeks 
old at day 14 after 
intense octave band 
noise for 2 to 3 hours 
and six controls. 
Auditory brainstem 
responses 
- Tone-pips (5 ms 
duration at a rate of 
21/s, 2 ms rise-fall 
time) at 8, 16, and 
24 kHz from 90 dB 
SPL in steps of 
minimum 5 dB. 
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otoacoustic emissions 
- 70/70 dB SPL, 
f1:f2=1.2 






decrease in prestin 
concentrations 14 
days post-exposure 
LAG, low aminoglycoside group; HAG, high aminoglycoside group; HCIS, high cisplatin; LCIS, low 
cisplatin 
